← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 PTC Therapeutics PTCT $5.09B	176	+2	+1%	$2.63B
27	27 Ultragenyx Pharmaceutical RARE $1.5B	170	-7	-4%	$3.74B
28	NVTA 28 DELISTED Invitae Corporation NVTA	162	-21	-11%	$1.95B
29	29 Precigen PGEN $2.58B	162	-4	-2%	$943M
30	30 Pacific Biosciences PACB $609M	150	-10	-6%	$733M
31	31 Intellia Therapeutics NTLA $1.59B	144	-4	-3%	$635M
32	32 uniQure QURE $1.56B	144	+15	+12%	$2.07B
33	NSTG 33 DELISTED NanoString Technologies, Inc. NSTG	138	+3	+2%	$1.07B
34	34 Vericel Corp VCEL $2.1B	137	-28	-17%	$740M
35	35 Fate Therapeutics FATE $231M	136	+13	+11%	$1.28B
36	36 Standard BioTools LAB $258M	135	+4	+3%	$872M
37	37 Voyager Therapeutics VYGR $127M	125	+14	+13%	$796M
38	38 Atara Biotherapeutics ATRA $96.9M	116	-4	-3%	$1.01B
39	39 Adaptive Biotechnologies ADPT $4.08B	111	+111	–	$3.74B
40	40 Lineage Cell Therapeutics LCTX $250M	107	-11	-9%	$71.2M
41	41 Lakefront Biotherapeutics American Depositary Shares LKFT $1.96B	102	+10	+11%	$1.11B
42	42 Wave Life Sciences WVE $629M	100	-10	-9%	$795M
43	43 Abeona Therapeutics ABEO $266M	98	+11	+13%	$138M
44	ATHX 44 DELISTED Athersys, Inc. Common Stock ATHX	98	-2	-2%	$56.7M
45	45 Rocket Pharmaceuticals RCKT $259M	96	+15	+19%	$736M
46	46 DELISTED Adverum Biotechnologies ADVM	94	+11	+13%	$549M
47	47 Allogene Therapeutics ALLO $463M	94	+8	+9%	$1.85B
48	ATNX 48 DELISTED Athenex, Inc. Common Stock ATNX	91	+15	+20%	$732M
49	49 Twist Bioscience TWST $9.58B	85	+36	+73%	$402M
50	50 Invesco Biotechnology & Genome ETF PBE $429M	81	0	0%	$66.4M